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Figure	1.1	Traditional	VIN	classification.	Figure	represents	the	vulval	epithelium	with	increasing	grade	of	VIN	moving	from	left	to	right.	VIN	1	illustrated	involving	<1/3	of	epithelium,	VIN	2	involving	up	to	2/3	of	epithelium	and	VIN	3	involving>2/3	of	epithelium.	Histological	features	labelled.	Invasive	cancer	displays	invasion	through	the	basement	membrane.	Adapted	from	figure	drawn	by	Dr	Amanda	Tristram.		The	classification	was	modified	in	2004	by	the	ISSVD	upon	the	recognition	of	two	different	modes	of	pathogenesis	leading	to	disease;	the	more	common	usual	VIN	(uVIN)	being	HPV	dependent	and	the	less	common	differentiated	VIN	(dVIN),	which	is	HPV	independent	(Sideri	et	al.	2005).	The	subtypes	are	differentiated	histologically.	Histological	features	of	uVIN	remain	the	same	as	those	used	for	CIN.	The	histological	features	for	dVIN	are	subtle,	and	include:	•	 Atypical	keratinocytes	in	the	context	of	a	fully	differentiated	vulval	epithelium	•	 Thickened	epidermis	with	parakeratotic	surface	reaction	•	 Elongated	rete	ridges,	frequently	branched	•	 A	significant	number	of	abnormal	enlarged	squamous	cells	with	large	vesicular	nuclei	and	macronuclei.	















































































































































































































































































al.	1991	 1991	 19	 HPV	16	type-specific	PCR	 N/S	 78.9	 78.9	Nuovo	et	al.	1991	 1991	 22	 MY09/11	 N/S	 59.1	 40.9	Park	et	al.	1991	 1991	 30	MY09/11	and	type-specific	HPV	6/11/16/18	 N/S	 53.3	 53.3	Torre	et	al.	1992	 1992	 7	 HPV	16	type-specific	PCR	 N/S	 100	 100	Pilotti	et	al.	1995	 1995	 5	 HPV	16	type-specific	PCR	 N/S	 100	 100	Junge	et	al.	1995	 1995	 58	 HPV	6/11/16/18/31/33	type-specific	PCR				
N/S	 88	 77.6	
Van	Beurden	et	
al.	1995	 1995	 46	 CpI/IIG	 N/S	 95.7	 89.1	Trimble	et	
al.	1996	 1996	 54	 Digene	 N/S	 89	 N/S	Nagano	et	
al.	1996	 1996	 6	 L1	PCR	 N/S	 100	 66.7	Madeleine	
et	al.	1997	 1997	 253	 MY09/11	and	TS	HPV	6/11/16/18/45/31	 N/S	 71.5	 61.7	Pinto	et	al.	1999	 1999	 16	 PCR	L1	Consensus	primers	 uVIN	 67	 N/S	Carter	et	al.	2001	 2001	 18	 PGMY9/11	 N/S	 91	 74.6	Abdel-Hady	
et	al.	2001	 2001	 19	 GP5+/6+	and	TS	HPV	6/11/16/18/31/33	 N/S	 73.7	 64.3	Logani	et	al.	2003	 2003	 6	 SPF10	 uVIN	 100	 66.6	Riethdorf	et	
al.	2004	 2004	 39	 GP5+/6+	and	HPV	16	E6/E7	ISH	 N/S	 100	 100	Bryndorf	et	
al.	2004	 2004	 11	 SPF10	 N/S	 81.8	 63.6	Todd	et	al.	2004	 2004	 10	 GP5+/6+	 N/S	 90.0	 50.0	Bonvicini	et	
al.	2005	 2005	 25	 MY09/11	 uVIN	(n=18)dVIN	(n=7)	 61.1	0	 50	0	Rufforny	et	


















Srodon	et	al.	2006	 2006	 34	 PGMY09/11	and	SPF10	 N/S	 100	 91	Hample	et	
al.	2007	 2007	 49	 GP5+/6+	and	MY09/11	 N/S	 91.8	 67.3	Skapa	et	al.	2007	 2007	 33	 GP5+/6+	 uVIN	 100	 76.1	Van	Seters	
et	al.	2007	 2007	 26	 GP5+/6+	 uVIN	 30.8	 26.9	(van	Seters,	Beckmanet	
al.	2008)	 2008	 52	 GP5+/6+	 N/S	 96.2	 78.8	Van	de	Nieuwenhof,	van	Kempen	
et	al.	2009	 2009	 13	 PCR	L1	 uVIN	 100	 44	Garland	et	
al.	2009	 2009	 62	 PCR	 uVIN	 84	 42	Smith	et	al.	2009	 2009	 65	 PGMY9/11	 N/S	 98	 50	Gargano	et	
al.	2012	 2011	 66	 PGMY9/11	 N/S	 94	 48	Tachezy	et	
al.	2011	 2011	 46	 GP5+/6+	 uVIN	 100	 71.7	Tsimplaki	et	
al.	2012	 2012	 28	 PapilloCheck	 uVIN	 71	 65	De	Sanjose	

































































Study	 Formulation	 Strength	 Dosing	Snoeck	et	al.	2001	 Gel	(20%	propylene	glycol,	2%	hydroxyethylcellulose,	0.18%	methylparaben,	0.02%	propylparaben,	0.02%	edetate	disodium	and	1%	cidofovir	
1%	 Daily	for	5	consecutive	days	every	other	week	for	12	weeks.	



























































































Diaz-Arrastia	et	al.	2001	 8	 4/8	(50.0)	 2/8	(20.0)	 2/4(50%)	 Mean	33	months	 	Jayne	et	al.	2002	 13	 8/13	(61.5)	 4/13	(30.8)	 Not	reported	 5.5	months	 	Todd	et	al.	2002	 15	 3/15	(20.0)	 1/15	(6.7)	 Not	reported	 5	months	 Local	side	effects	limited	treatment	application	so	that	7	patients	only	applied	the	cream	once	a	week,	6	patients	applied	in	twice	a	week	and	only	2	patients	adhered	to	the	treatment	protocol	of	three	times	a	week.	Davis	et	al.	2000	 4	 4/4	(100.0)	 0/4	(0.0)	 2/4	(50.0%)	 12	months	 In	the	2	cases	of	recurrence,	one	cases	has	a	recurrence	in	the	perianal	region	and	another	had	a	recurrence	in	a	region	outside	of	the	previously	treated	field.	Van	Seters	et	al.	2002	 15	 4/15	(26.6)	 9/15	(60.0)	 0	 Not	reported	 	Marchitelli	et	al.	2004	 8	 7/8	(87.5)	 1/8	(12.5)	 0	 Range	10-30	months	 	Wendling	et	al.	2004	 12	 3/12	(25.0)	 4/12	(33.3)	 0	 Mean	9.7	months	 	Mathiesen	et	al.	2004	 32	 17/21	(81.0%)	 2/21(10.0%)	 Not	reported	 Not	reported	 14/21	patients	had	to	reduce	the	frequency	of	cream	applications	due	to	side	
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To investigate HPV 
biology in VIN
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ajority of cases of VIN will be 
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Primer&Type& HPV&16&E6&Primer&sequence& Product&size&HPV!16!E6!Forward!primer!HPV!16!E6!Reverse!primer! GAACAGCAATACAACAAACC!GATCTGCAACAAGACATACA! ! 161!bp!
Primer&Type& HPV&16&E7&Primers&sequence& Product&size&HPV!16!E7!forward!primer&HPV!16!E7!reverse!primer!
&
GATGAAATAGATGGTCCAGC&GCTTTGTACGCACAACCGAAGC& !100bp!HPV!18!E7!forward!primer&HPV!18!E7!reverse!primer& AAGAAAACGATGAAATAGATGGA!GGCTTCACACTTACAACACA! !!100!bp!!HPV!31!E7!forward!primer!HPV!31!E7$reverse!primer! GGGCTCATTTGGAATCGTGTG!AACCATTGCATCCCGTCCCC!! !100!bp!HPV!33!E7!forward!primer!HPV!33!E7!reverse!primer! TGAGGATGAAGGCTTGGACC!TGACACATAAACGAACTGTG!! !100!bp!HPV!35!E7!forward!primer!HPV!35!E7!reverse!primer! CTATTGACGGTCCAGCT!TACACACAGACGTAGTGTCG!! !100!bp!HPV!51!E7!forward!primer!HPV!51!E7!reverse!primer! TACGTGTTACAGAATTGAAG!AACCAGGCTTAGTTCGCCCATT!! !100!bp!
Primer&Type! HPV&16&E2&Primers&sequence Product&size!HPV!16!E2>1!forward!HPV!16!E2>1!reverse! AGGACGTGGTCCAGATTAAG!TCAAACTGCACTTCCACTGT! !418!bp!HPV!16!E2>2!forward!HPV!16!E2>2!reverse! TAACTGCACCAACAGGATGT!GCCAAGTGCTGCCTAATAAT!! !340!bp!HPV!16!E2>3!forward!HPV!16!E2>3!reverse! ATCTGTGTTTAGCAGCAACG!TAAATGCAGTGAGGATTGGA!! !223!bp!HPV!16!E2>4!forward!HPV!16!E2>4!reverse! ACAGTGCTCCAATCCTCACT!TCACGTTGCCATTCACTATC!! !243!bp!HPV!16!E2>5!forward!HPV!16!E2>5!reverse! GGCATTGGACAGGACATAAT!CAAAAGCACACAAAGCAAAG!! !206!bp!





































































	 Temp	(˚C)	 Time	(secs)	 Cycles	
Initial	Denaturation	 95	 600	 1	






























































































































































































































































Forward	Primer	 5	μM	 2	 2	 2	 2	
Reverse	Primer	 5	μM	 2	 2	 2	 2	
FS	Mix	 -	 2	 2	 2	 2	
MgCl2	 25mM	 1.6	 1.2	 2	 2.4	





2	 2	 2	 2	
	 Temp	(°C)	 Time	(secs)	 Cycles	















	 Temp	(°C)	 Rate	of	Change	(°C/sec)	 Cycles	





















3.2.1 Trial	Design	To	assess	the	activity,	safety	and	feasibility	of	treatment	of	VIN	3	with	topical	cidofovir	and	5%	 concentration	 imiquimod,	 a	 phase	 II	 randomised	 controlled	 trial	was	 designed.	 UK-wide,	 multi-centre	 recruitment	 was	 established	 and	 in	 total,	 32	 centres	 were	 involved.	Ethical	 approval	 was	 obtained	 from	 the	 Research	 Ethics	 Committees	 Northern	 Ireland	(08/NIR03/82).	 Regulatory	 approval	 was	 also	 obtained	 from	 the	 Medicines	 and	Healthcare	 Products	 Regulatory	 Agency	 (MHRA)	 under	 the	 Medicines	 for	 Human	 Use	(Clinical	 Trials)	 Regulations	 2004	 S.I	 2004/1031	 (reference	 number	 21323/0020/001-
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Biopsy proven VIN 3
•  Trial eligibility
•  Consent







Optional research biopsy taken 6 
weeks following start of treatment
6 weekly follow up for 24 weeks 
or until disease clearance
6 week post-treatment visit:
•  Clinical assessment
•  Biopsy for histology
•  Research biopsy
•  Optional cross-over treatment if no 
response



























































n=	 %	 n=	 %	




























































Lost to follow up 
n=5
Lost to follow up 
n=3 Withdrew n=15 No biopsy n=2
Final cidofovir for analysis 
n=72
No biopsy n=2Withdrew n=12
VIN absent n= 42 
(60.9%)
VIN present n=31 
(43.1%)
VIN absent  n= 41 
(56.9%)
Final imiquimod for 
analysis n=69























































































































































HPV	16	test	results	 n=	 E1	intact	(%)**	 E1	disrupted	(%)*	
PapilloCheck®	+ve	and	HPV	16	E6	PCR	+ve	 110	 90	(81.8)	 20	(18.2)	
PapilloCheck®	+ve	and	HPV	16	E6	PCR	-ve	 1	 0	 1	(100)	
PapilloCheck®	-ve	and	HPV	16	E6	PCR	+ve	 25	 0	 25	(100)	
PapilloCheck®	-ve	and	HPV	16	E6	PCR	-ve	 31	 0	 31	(100)	



















































Sample	1	 Negative	 Negative	 16	
Sample	2	 Negative	 Negative	 16	
Sample	3	 Negative	 Negative	 33	
Sample	4	 Negative	 Negative	 33	
Sample	5	 Negative	 Negative	 33	
Sample	6	 Negative	 Negative	 51	
Sample	7	 Negative	 Negative	 73	
Sample	8	 Negative	 Negative	 16,33	
Sample	9	 Negative	 Negative	 16,33	
Sample	10	 Negative	 Negative	 42,51	
Sample	11	 Negative	 Negative	 Negative	
Sample	12	 Negative	 Negative	 Negative	
Sample	13	 Negative	 Negative	 Negative	
Sample	14	 Negative	 Negative	 Negative	
Sample	15	 42	 Negative	 42	
Sample	16	 42	 Negative	 42	
Sample	17	 16	 16	 16	
Sample	18	 16	 16	 16	
Sample	19	 16	 16	 16	
Sample	20	 16	 16	 16	
Sample	21	 16	 16	 16	
Sample	22	 16	 16	 16	
Sample	23**	 16	 16	 42	




















































Case$number E6$result E181 E182 E281 E282 E283 E284 E285 Case$number E6$result E181 E182 E281 E282 E283 E284 E285
case%1* 0 0 0 0 0 0 0 0 case%69 1 1 0 1 1 1 1 1
case%2 1 0 0 0 0 0 0 0 case%70 1 0 1 1 1 1 1 1
case%3 1 0 0 0 0 0 0 0 case%71 1 0 1 1 1 1 1 1
case%4 1 0 0 0 0 0 0 0 case%72 1 1 1 1 1 1 1 1
case%5 1 0 0 0 0 0 0 0 case%73 1 1 1 1 1 1 1 1
case%6 1 0 0 0 0 0 0 0 case%74 1 1 1 1 1 1 1 1
case%7 1 0 0 0 0 0 0 0 case%75 1 1 1 1 1 1 1 1
case%8 1 0 0 0 0 0 0 0 case%76 1 1 1 1 1 1 1 1
case%9 1 1 0 0 0 0 0 0 case%77 1 1 1 1 1 1 1 1
case%10 1 1 0 0 0 0 0 0 case%78 1 1 1 1 1 1 1 1
case%11 1 1 0 0 0 0 0 0 case%79 1 1 1 1 1 1 1 1
case%12 1 1 0 0 0 0 0 0 case%80 1 1 1 1 1 1 1 1
case%13 1 1 0 0 0 0 0 0 case%81 1 1 1 1 1 1 1 1
case%14 1 1 0 0 0 0 0 0 case%82 1 1 1 1 1 1 1 1
case%15 1 1 0 0 0 0 0 0 case%83 1 1 1 1 1 1 1 1
case%16 1 1 0 0 0 0 0 0 case%84 1 1 1 1 1 1 1 1
case%17 1 1 0 0 0 0 0 0 case%85 1 1 1 1 1 1 1 1
case%18 1 1 0 0 0 0 0 0 case%86 1 1 1 1 1 1 1 1
case%19 1 1 0 0 0 0 0 0 case%87 1 1 1 1 1 1 1 1
case%20 1 1 0 0 0 0 0 0 case%88 1 1 1 1 1 1 1 1
case%21 1 1 0 0 0 0 0 0 case%89 1 1 1 1 1 1 1 1
case%22 1 1 1 0 0 0 0 0 case%90 1 1 1 1 1 1 1 1
case%23 1 1 1 0 0 0 0 0 case%91 1 1 1 1 1 1 1 1
case%24 1 1 1 0 0 0 0 0 case%92 1 1 1 1 1 1 1 1
case%25 1 1 1 0 0 0 0 0 case%93 1 1 1 1 1 1 1 1
case%26 1 1 1 1 0 0 0 0 case%94 1 1 1 1 1 1 1 1
case%27 1 1 1 1 0 0 0 0 case%95 1 1 1 1 1 1 1 1
case%28 1 1 1 1 0 0 0 0 case%96 1 1 1 1 1 1 1 1
case%29 1 1 0 0 1 0 0 0 case%97 1 1 1 1 1 1 1 1
case%30 1 1 1 1 1 0 0 0 case%98 1 1 1 1 1 1 1 1
case%31 1 1 1 1 1 0 0 0 case%99 1 1 1 1 1 1 1 1
case%32 1 1 1 0 0 0 1 0 case%100 1 1 1 1 1 1 1 1
case%33 1 0 0 1 1 1 1 0 case%101 1 1 1 1 1 1 1 1
case%34 1 0 0 1 1 1 1 0 case%102 1 1 1 1 1 1 1 1
case%35 1 1 0 1 1 1 1 0 case%103 1 1 1 1 1 1 1 1
case%36 1 1 1 1 1 1 1 0 case%104 1 1 1 1 1 1 1 1
case%37 1 1 1 1 1 1 1 0 case%105 1 1 1 1 1 1 1 1
case%38 1 1 1 1 1 1 1 0 case%106 1 1 1 1 1 1 1 1
case%39 1 1 1 1 1 1 1 0 case%107 1 1 1 1 1 1 1 1
case%40 1 1 1 1 1 1 1 0 case%108 1 1 1 1 1 1 1 1
case%41 1 1 1 1 1 1 1 0 case%109 1 1 1 1 1 1 1 1
case%42 1 1 1 1 1 1 1 0 case%110 1 1 1 1 1 1 1 1
case%43 1 1 1 1 1 1 1 0 case%111 1 1 1 1 1 1 1 1
case%44 1 1 1 1 1 1 1 0 case%112 1 1 1 1 1 1 1 1
case%45 1 1 1 1 1 1 1 0 case%113 1 1 1 1 1 1 1 1
case%46 1 1 1 1 1 1 1 0 case%114 1 1 1 1 1 1 1 1
case%47 1 0 0 0 0 0 0 1 case%115 1 1 1 1 1 1 1 1
case%48 1 0 0 0 0 0 0 1 case%116 1 1 1 1 1 1 1 1
case%49 1 0 0 0 0 1 0 1 case%117 1 1 1 1 1 1 1 1
case%50 1 1 0 0 0 1 0 1 case%118 1 1 1 1 1 1 1 1
case%51 1 1 0 1 1 1 0 1 case%119 1 1 1 1 1 1 1 1
case%52 1 1 0 0 0 0 1 1 case%120 1 1 1 1 1 1 1 1
case%53 1 1 1 1 0 0 1 1 case%121 1 1 1 1 1 1 1 1
case%54 1 0 0 0 0 1 1 1 case%122 1 1 1 1 1 1 1 1
case%55 1 1 1 0 0 1 1 1 case%123 1 1 1 1 1 1 1 1
case%56 1 1 1 0 0 1 1 1 case%124 1 1 1 1 1 1 1 1
case%57 1 0 0 0 1 1 1 1 case%125 1 1 1 1 1 1 1 1
case%58 1 1 0 0 1 1 1 1 case%126 1 1 1 1 1 1 1 1
case%59 1 1 1 0 1 1 1 1 case%127 1 1 1 1 1 1 1 1
case%60 1 0 0 1 1 1 1 1 case%128 1 1 1 1 1 1 1 1
case%61 1 0 0 1 1 1 1 1 case%129 1 1 1 1 1 1 1 1
case%62 1 0 0 1 1 1 1 1 case%130 1 1 1 1 1 1 1 1
case%63 1 0 0 1 1 1 1 1 case%131 1 1 1 1 1 1 1 1
case%64 1 0 0 1 1 1 1 1 case%132 1 1 1 1 1 1 1 1
case%65 1 0 0 1 1 1 1 1 case%133 1 1 1 1 1 1 1 1
case%66 1 1 0 1 1 1 1 1 case%134 1 1 1 1 1 1 1 1
case%67 1 1 0 1 1 1 1 1 case%135 1 1 1 1 1 1 1 1



























































E1	intact	 65	 25	 90	
E1	disrupted	 12	 34	 46	














































































































































































































CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
E2	CpG1	(nt*	3411)	 23.25	 0.00	 92.37	 32.16	
E2	CpG2	(nt	3414)	 22.03	 0.00	 99.81	 34.80	
E2	CpG3	(nt	3416)	 18.31	 0.00	 83.00	 29.37	
E2	CpG4	(nt	3432)	 26.46	 0.00	 100.00	 35.36	
E2	CpG5	(nt	3435)	 22.70	 0.00	 99.57	 34.68	
E2	CpG6	(nt	3447)	 23.31	 0.00	 94.24	 32.28	
Promoter	region	methylation(n=114)	
CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
Promoter	CpG1	(nt	31)	 2.72	 0.00	 82.60	 11.41	
Promoter	CpG2	(nt	37)	 2.86	 0.00	 79.68	 11.47	
Promoter	CpG3	(nt	43)	 2.87	 0.00	 81.83	 11.94	
Promoter	CpG4	(nt	52)	 3.29	 0.00	 81.58	 12.01	
Promoter	CpG5	(nt	58)	 2.51	 0.00	 73.17	 10.71	
L1/L2	region	methylation(n=60)	
CpG	site	 Mean	(%)	 Min	(%)	 Max	(%)	 Std.	Dev	
L1/L2	CpG1	(nt	5615)	 32.77	 0.00	 85.25	 32.65	
L1/L2	CpG2	(nt	5606)	 46.08	 0.00	 92.05	 37.77	
L1/L2	CpG3	(nt	5609)	 40.82	 0.00	 97.19	 39.46	






E2	Region		 CpG1–CpG2	 CpG2–CpG3	 CpG3–CpG4	 CpG4–CpG5	 CpG5–CpG6	
Ζ	statistic	 -3.070	 -4.677	 -6.942	 -6.610	 -2.094	
P	value	 0.002	 <0.001	 <0.001	 <0.001	 0.036	
L1/L2	region		 CpG1-CpG2	 CpG2-CpG3	 CpG3-CpG4	 	 	
Ζ	statistic	 -6.680	 -5.110	 -6.552	 	 	
P	value	 <0.001	 <0.001	 <0.001	 	 	
Promoter	region		 CpG1-CpG2	 CpG2-CpG3	 CpG3-CpG4	 CpG4-CpG5	 	
Ζ	statistic	 -1.292	 -0.158	 -4.359	 -5.857	 	












































  E2 E6 E7 HPRT TBP 
                Valid results n= 115 120 119 122 122 
Missing* 21 16 17 14 14 
Mean 1.88 1.01 1.20 0.43 0.40 
Median 2.40 1.02 1.23 0.47 0.36 
Std. Deviation 1.30 0.48 0.49 0.23 0.23 
Range 3.68 2.19 2.32 0.83 0.83 
Minimum 0.00 0.00 0.00 0.00 0.00 
Maximum 3.68 2.19 2.32 0.83 0.83 






































































































































































	 Mean	 Median	 Significance	
E2>E6	 12.04	 3.2	 P=0.008	
E6>E2	 36.4	 7.7	
L1/L2	methylation	
	 Mean	 Median	 Significance	
E2>E6	 21.0	 8.05	 P=0.004	
E6>E2	 46.3	 42.9	
Promoter	methylation	
	 Mean	 Median	 Significance	
























































































































































































































































































































































































































































































































































































































































































































E2	meth	>	2.0%	 17	 7	 24	
E2	meth	<2.0%	 0	 6	 6	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	>2.0%	 100.0%	 46.15%	 70.8%	 100.0%	









E2	meth	>	4.0%	 15	 2	 17	
E2	meth	<4.0%	 2	 11	 13	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	>4.0%	 88.2%	 84.6%	 88.2%	 84.6%	









E2	meth	>	5.0%	 12	 1	 13	
E2	meth	<5.0%	 5	 12	 17	
Total	 17	 13	 30	
	 Sensitivity	 Specificity	 PPV	 NPV	





















































































































































E2	meth	<4	.0%	 12	 6	 18	
E2	meth	>4.0%	 5	 10	 15	
Total	 17	 16	 33	
	 Sensitivity	 Specificity	 PPV	 NPV	
E2	meth	<4.0%	 70.6%	 62.5%	 66.7%	 66.7%	












E2	meth	<10.0%	 14	 7	 21	
E2	meth	>10.0%	 3	 9	 12	
Total	 17	 16	 33	
	 Sensitivity	 Specificity	 PPV	 NPV	


































































































































































RT1	 06/11/09	 69	 2.2	 2.6	 7.5	
RT11	 21/12/09	 238	 2.1	 0.9	 2.2	
RT21	 28/01/10	 201	 2.1	 2.2	 1.2	
RT31	 12/02/10	 184	 2	 2	 7.8	
RT41	 20/08/10	 27	 2.2	 1.2	 n/a	
RT51	 28/08/10	 82	 2.0	 1.9	 4.3	
RT61	 20/08/10	 55	 2	 1.7	 n/a	
RT71	 12/01/11	 71	 2.1	 2	 1	
RT81	 28/01/11	 37	 2	 1.4	 n/a	
RT91	 08/02/11	 105	 2	 1.9	 1.5	
RT101	 10/03/11	 279	 2.1	 2.3	 2.4	
RT111	 30/03/11	 126	 2.1	 1.17	 1.5	
RT121	 05/04/11	 46	 2	 0.9	 1	
RT131	 12/04/11	 62	 2.1	 1.9	 1	
RT141	 10/05/11	 79	 2	 1.4	 4.2	
RT151	 24/05/11	 299	 2.	 2.1	 4.3	
RT161	 31/05/11	 78.1	 2	 1	 1	
RT171	 09/06/11	 137	 2.1	 2	 3.3	
RT181	 09/06/11	 280	 2	 2.1	 n/a	
RT191	 21/06/11	 49	 2	 1.8	 1.2	
RT200	 22/06/11	 180	 2	 2.1	 2.4	
RT211	 17/08/11	 21	 2.1	 1.1	 1	
RT221	 01/12/11	 267	 2.1	 2.1	 5.7	
RT231	 13/12/11	 164	 2	 1.3	 3.3	
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